Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 2, 2009, Pages 380-381

  Park, Young Min ^a   Lee, Heon Jeong ^b   Kang, Seung Gul ^b   Choo, Chung Sook ^a   Cho, Jae Hyuck ^a  

^a Inje University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; CIMETIDINE; CITALOPRAM; ESCITALOPRAM; ITOPRIDE; LORAZEPAM;

ADD ON THERAPY; AGED; ANOREXIA; ANXIETY; ARM; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HEARTBURN; HUMAN; LETTER; MAJOR DEPRESSION; MOOD DISORDER; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA;

AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZAMIDES; BENZYL COMPOUNDS; BUPROPION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LORAZEPAM;

EID: 60049093582     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.12.001     Document Type: Letter

References (15)

1. Andreassen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog Neurobiol 61 (2000) 525-541
2. Baldessarini R.J., and Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry 47 (1990) 191-192
3. Bouchard R.H., Pourcher E., and Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146 (1989) 1352-1353
4. Brod T.M. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 146 (1989) 1353
5. Casey D.E., Gerlach J., Magelund G., and Christensen T.R. Gamma-acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 37 (1980) 1376-1379
6. Dubovsky S.L., and Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv 47 (1996) 991-993
7. Ganzini L., Casey D.E., Hoffman W.F., and McCall A.L. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153 (1993) 1469-1475
8. Holtmann G., Talley N.J., Liebregts T., Adam B., and Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 354 (2006) 832-840
9. Kennedy C., Hunter C., Davidson A., and Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 48 (2008) 379-384
10. Korsgaard S., Gerlach J., and Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118 (1985) 245-252
11. Mander A., McCausland M., Workman B., Flamer H., and Christophidis N. Fluoxetine induced dyskinesia. Aust N Z J Psychiatry 28 (1994) 328-330
12. Sandler N.H. Tardive dyskinesia associated with fluoxetine. J Clin Psychiatry 57 (1996) 91
13. Samad N., Khan A., Perveen T., Haider S., Abdul Haleem M., Haleem D.J., et al. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia. Acta Neurobiol Exp 67 (2007) 389-397
14. Stevens J.E., Russo A., Maddox A.F., Rayner C.K., Phillips L., and Talley N.J. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil 20 (2008) 456-463
15. Tarsy D., and Baldessarini R.J. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?. Mov. Disord. 21 (2006) 589-598